Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2025)

Vivos Therapeutics' EBITDA Margin history spans 6 years, with the latest figure at 172.12% for Q4 2025.

  • Quarterly results put EBITDA Margin at 172.12% for Q4 2025, down 9895.0% from a year ago — trailing twelve months through Dec 2025 was 110.07% (down 3840.0% YoY), and the annual figure for FY2025 was 110.04%, down 3905.0%.
  • EBITDA Margin for Q4 2025 was 172.12% at Vivos Therapeutics, down from 63.9% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 200.5% in Q4 2021 to a low of 176.7% in Q1 2022.
  • The 5-year median for EBITDA Margin is 119.18% (2021), against an average of 98.18%.
  • The sharpest move saw EBITDA Margin skyrocketed 38987bps in 2021, then crashed -34640bps in 2022.
  • Year by year, EBITDA Margin stood at 200.5% in 2021, then plummeted by -173bps to 145.9% in 2022, then increased by 17bps to 121.09% in 2023, then skyrocketed by 40bps to 73.17% in 2024, then crashed by -135bps to 172.12% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 172.12%, 63.9%, and 119.5% for Q4 2025, Q3 2025, and Q2 2025 respectively.